Pharvaris N.V. $PHVS Shares Acquired by Stempoint Capital LP

Stempoint Capital LP increased its holdings in shares of Pharvaris N.V. (NASDAQ:PHVS) by 48.4% in the first quarter, Holdings Channel reports. The firm owned 86,637 shares of the company’s stock after acquiring an additional 28,248 shares during the period. Stempoint Capital LP’s holdings in Pharvaris were worth $2,447,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. California State Teachers Retirement System increased its holdings in Pharvaris by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after purchasing an additional 520 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Pharvaris in the fourth quarter worth about $35,000. Public Employees Retirement System of Ohio boosted its position in shares of Pharvaris by 20.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after buying an additional 1,300 shares during the period. Finally, Legal & General Group Plc grew its stake in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after buying an additional 1,695 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Royal Bank Of Canada dropped their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Wedbush upped their price target on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Wolfe Research initiated coverage on shares of Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective for the company. Citizens Jmp dropped their price objective on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 13th. Finally, Citigroup reissued a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.08.

Pharvaris Price Performance

Shares of Pharvaris stock opened at $32.62 on Thursday. Pharvaris N.V. has a 1-year low of $19.12 and a 1-year high of $36.60. The company has a market capitalization of $2.13 billion, a PE ratio of -10.26 and a beta of -2.34. The business has a 50-day moving average of $32.71 and a 200-day moving average of $29.45.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.12. On average, equities analysts expect that Pharvaris N.V. will post -2.97 earnings per share for the current fiscal year.

Insider Activity at Pharvaris

In other Pharvaris news, insider Anne Lesage sold 27,872 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.48, for a total value of $988,898.56. Following the transaction, the insider directly owned 58,750 shares of the company’s stock, valued at $2,084,450. This represents a 32.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO David W. Nassif sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $30.31, for a total value of $303,100.00. Following the completion of the transaction, the chief financial officer directly owned 120,300 shares in the company, valued at approximately $3,646,293. The trade was a 7.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 178,322 shares of company stock worth $5,969,286 over the last ninety days. Company insiders own 11.84% of the company’s stock.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.